Abstract:Abstract Background The receptor tyrosine kinase FLT3 with internal tandem duplications within the juxtamembrane domain ( FLT3 -ITD) is a poor prognostic factor; however, the prognostic significance of missense mutation in the tyrosine kinase domain ( FLT3 -TKD) is controversial. Furthermore, the accompanying mutations and fusion genes with FLT3 mutations are unclear in acute myeloid leukemia (AML). Methods We investigated FLT3 mutations and their correlation with other gene mutations and gene fusions through two RNA-seq based next-generation sequencing (NGS) method and prognostic impact in 207 de novo AML patients. Results FLT3 -ITD mutations were positive in 58 patients (28%), and FLT3 -TKD mutations were positive in 20 patients (9.7%). FLT 3-ITD was associated with a higher white blood cell count (WBC, mean 72.9 × 10 9 /L vs. 24.2 × 10 9 /L, P = 0.000), higher bone marrow blasts (mean 65.9% vs. 56.0%, P = 0.024), and NK-AML (normal karyotype) (64.8% vs. 48.4%, P = 0.043). NPM1 and DNMT3A mutations were enriched in FLT3 -ITD (53.5% vs. 15.3%, P = 0.000; 34.6% vs. 13%, P = 0.003). However, the mutations of CEBPA were excluded in FLT3 -AML (3.8% vs. 0% vs. 19.8%, P = 0.005). Mutations of Ras and TP53 were unlikely associated with FLT3 -ITD (1.9% vs. 20.6%, P = 0.006; 0% vs. 6.1%, P = 0.04). The common fusion genes (> 10%) in FLT3 -ITD had MLL- rearrangement and NUP98 -rearrangement, while the common fusion genes in FLT3 -TKD had AML1-ETO and MLL -rearrangement. Two novel fusion genes PRDM16-SKI and EFAN2-ZNF238 were identified in FLT3-ITD patients. Gene fusions and NPM1 mutation were mutually excluded in FLT3 -ITD and FLT3 -TKD patients. Their patterns of mutual exclusivity and cooperation among mutated genes suggest that additional driver genetic alterations are required and reveal two evolutionary patterns of FLT3 pathogenesis. Patients with FLT3 -ITD had a lower CR (complete remission) rate, lower 3-year OS (overall survival), DFS (disease-free survival), and EFS (event-free survival) compared to FLT3 wt AML. NK-AML with FLT3 -ITD had a lower 3-year OS, DFS, and EFS than those without, while FLT3 -TKD did not influence the survival in whole cohort and NK-AML. Besides, we found that FLT3 -ITD/ TET2 bimutation defined a poor prognostic subgroup. Conclusions Our study offers deep insights into the molecular pathogenesis and biology of AML with FLT3 -ITD and FLT3 -TKD by providing the profiles of concurrent molecular alterations and the clinical impact of FLT3 -ITD and FLT3 -TKD on AML patients.

DNMT3A Co-Mutation is Required for FLT3-ITD As an Adverse Prognostic Indicator in Intermediate-Risk Cytogenetic Group AML.

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Co-mutation Landscape and Its Prognostic Impact on Newly Diagnosed Adult Patients with NPM1 Mutated De Novo Acute Myeloid Leukemia.

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival

Correlation of the Poor Prognosis of Acute Myeloid Leukemia Withflt3-Itd Anddnmt3a Mutations

The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia

Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns

Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients

Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients

Expression of KDR Plus Detection of Flt3-ITD and NPM1 Mutation as a Prognostic Marker in AML Patients with Normal Karyotype.

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

P3.02-080 DNMT3A Defines a Unique Molecular Class of Chinese Non-Small Cell Lung Cancer Patients

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia

Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients

[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations]

[Analysis of DNMT3a gene mutations in acute myelogenous leukemia]

Clinical characteristics of acute myeloid leukemia with DNMT3A R882 mutation

DNMT3A R882 mutation in children with acute myeloid leukemia and its role in prognosis